Three Ways to Enter the Neurostimulation Business

"Neurostimulators advanced technologies" is not one business model, it is at least three, and a lender or investor will spot within thirty seconds which one your plan is actually describing. Before you write a single financial projection, decide which of these you are building, because the capital requirement, timeline, and regulatory pathway are completely different for each.

Model 1: Implantable Device Manufacturer (Class III)

You design and manufacture a device that is surgically implanted, a spinal cord stimulator, deep brain stimulator, or vagus nerve stimulator. This is the highest-capital, highest-risk, highest-reward path. It requires FDA Premarket Approval (PMA), a pivotal clinical trial, and typically 3-5 years before first commercial revenue. Companies like Nevro Corp and Saluda Medical took this route and it demands $2.5M-$4.2M+ in pre-revenue capital, usually raised across multiple rounds plus non-dilutive grant funding.

Model 2: Non-Invasive / Wearable Neurostimulation Device Maker (Class II)

You design a transcutaneous or externally-worn neurostimulation device, for chronic pain, migraine, or sleep, that clears the FDA 510(k) pathway by showing substantial equivalence to an existing predicate device. This is materially faster (4-9 months FDA review vs. years) and cheaper ($850K-$2.1M pre-revenue), and is the realistic entry point for most first-time medtech founders in this niche.

Model 3: Neuromodulation Therapy Clinic / Service Provider

You don't manufacture hardware at all, you operate a clinical practice that delivers neurostimulation therapy using devices from Medtronic, Boston Scientific, or similar OEMs, billing per procedure or per episode of care. This model has the lowest capital requirement ($200K-$900K for a single-site clinic) but the revenue ceiling is capped by procedure volume and reimbursement rates rather than product margin.

Everything below is written primarily for Model 1 and Model 2 founders, the device-maker path, since that's what most searchers using this exact phrase are building. Where the clinic model differs meaningfully, we've flagged it.

Target Market & Buyer Segments

A neurostimulator device business plan needs to name three distinct buyer groups, because each one evaluates the product on completely different criteria, and a plan that treats them as one undifferentiated "healthcare market" reads as unresearched to anyone who works in medtech.

• Prescribing clinicians (neurologists, pain specialists, neurosurgeons): evaluate a device on peer-reviewed clinical evidence, ease of programming, and whether it fits an existing procedural workflow. This group controls adoption more than the end patient does.
• Health system procurement and value analysis committees: evaluate total cost of ownership, reimbursement certainty, and comparative effectiveness data against incumbent devices from Medtronic, Boston Scientific, or Abbott. A new entrant without at least one published comparative study will struggle here regardless of device performance.
• Patients and, increasingly, direct-to-consumer buyers of non-invasive devices: evaluate on price, comfort, ease of use, and, for chronic pain and migraine indications, whether the device avoids the side-effect profile of pharmaceutical alternatives. This segment is the primary buyer for Model 2 wearable devices and is largely irrelevant for Model 1 implantable systems, where the clinician is functionally the buyer.

For a Class III implantable device, your go-to-market plan and financial model should weight clinician and procurement relationships heavily, key opinion leader (KOL) engagement, conference presence at meetings like the North American Neuromodulation Society (NANS) annual conference, and peer-reviewed publication strategy are effectively part of your sales and marketing budget, not optional extras. For a Class II wearable, patient acquisition economics (paid search, partner clinic referral fees, DTC advertising) look much more like a conventional consumer health device launch, and your plan should model customer acquisition cost accordingly.

Startup Costs: Where the Money Actually Goes

For a non-invasive (Class II) neurostimulation device, realistic pre-revenue capital runs $850K to $2.1M (£670K-£1.65M). For a Class III implantable system pursuing full PMA, budget $2.5M to $4.2M+ (£2M-£3.3M) before you see meaningful commercial revenue, and that range excludes the cost of a large pivotal trial if your indication requires one.

Full Cost Breakdown

• Design, prototyping & bench testing (pulse generator + lead system): $180K-$650K (£142K-£512K)
• FDA pathway, PMA application fee (Class III, FY2025/26): $483,560 standard / $120,890 small-business rate
• FDA pathway, 510(k) fee (Class II, FY2026): $24,062 standard / $6,016 small-business rate
• ISO 13485:2016 QMS certification (BSI, TÜV SÜD, or equivalent Notified Body): $25K-$80K initial, $8K-$20K/yr surveillance
• Biocompatibility testing (ISO 10993 panel): $45K-$160K (£36K-£126K)
• Product liability & clinical trial insurance: $35K-$140K (£28K-£110K)
• Regulatory & clinical affairs staffing (Year 1): $150K-$520K (£118K-£410K)
• IP filing & prosecution (utility + design patents): $60K-$210K (£47K-£165K)
• Sales/clinical education infrastructure & launch marketing: $70K-$300K (£55K-£236K)

Funding Routes Specific to This Niche

The dominant early-stage funding route in implantable medtech is NIH SBIR/STTR grants, non-dilutive Phase I awards up to roughly $314,363 and Phase II awards up to roughly $2,095,748 (2025 hard-cap guidelines, higher for select topics), which many neurostimulation founders layer alongside seed equity rather than choosing one over the other. SBA 7(a) loans (up to $5M) can fund contract manufacturing and working capital once a device has clearance, but SBA lenders are typically unwilling to fund pre-clearance R&D risk. In the UK, Innovate UK smart grants and the Biomedical Catalyst programme are the closest equivalent to SBIR for early-stage medtech, alongside Start Up Loans (up to £25,000 at 6% fixed) for very early incorporation-stage costs. Most Series A rounds in this space are led by specialist medtech VCs rather than generalist funds, because diligence requires deep regulatory expertise.

SBA Lending Detail: Where This Category Actually Fits

SBA 7(a) data classified under NAICS 339112 (Surgical and Medical Instrument Manufacturing), the closest match for neurostimulator device manufacturers, shows loan approval activity concentrated at the post-revenue, post-clearance stage rather than pre-clearance R&D. Typical approved loan sizes for small medical device manufacturers in this NAICS code range from $150,000 to $2M, most commonly used for contract manufacturing scale-up, working capital, and equipment financing rather than the clinical and regulatory spend that dominates pre-clearance budgets. Live Oak Bank and Celtic Bank are among the most active SBA 7(a) lenders in the medtech manufacturing space nationally, alongside regional banks with dedicated healthcare lending desks. Because SBA lenders evaluate collateral and cash flow rather than clinical-stage IP value, a neurostimulator startup's SBA strategy should assume this debt becomes available only after FDA clearance, not before, plan pre-clearance capital entirely from equity, grants, and non-dilutive sources instead.

Contract Manufacturers & Component Suppliers

Almost no neurostimulator startup builds every component in-house. Your business plan should name the contract manufacturers and specialist suppliers you intend to qualify, because investors read a named supply chain as evidence you've actually scoped the build, not just the market opportunity.

• Integer Holdings (formerly Greatbatch), Plano, TX: the dominant contract manufacturer for implantable pulse generators, batteries, and feedthroughs, the default first call for a Class III device team
• NDH Medical / Nordson MEDICAL, Salem, NH: catheter and lead assembly, silicone overmolding for implantable leads
• Bioness-adjacent contract EMS providers (e.g. Flex Medical Solutions): PCB assembly and electronics manufacturing services for external/wearable neurostimulation controllers
• NAMSA (Northwood, OH) or Toxikon (Bedford, MA): ISO 10993 biocompatibility testing labs used to build the safety data package for both PMA and 510(k) submissions
• WuXi AppTec (Class III CDMO services) or Cirtec Medical (Brooklyn Park, MN): full-system design-to-manufacture partners for companies that don't want to build an in-house engineering team pre-clearance
• Avnet Silica or component distributors for implantable-grade microcontrollers and RF chipsets: sourcing partner once your bill of materials is locked
• BSI Group or TÜV SÜD: Notified Body / Certification Body for ISO 13485 and UKCA/CE conformity assessment

Building relationships with two qualified sources per critical component, not just one, is the single most common gap investors flag in early-stage medtech supply chain sections. A sole-sourced battery or lead assembly is a red flag in diligence.

Software & Quality Systems Tools

Alongside physical suppliers, name the software infrastructure your plan assumes. Greenlight Guru is the dominant eQMS (electronic Quality Management System) platform built specifically for medical device companies, handling Design History Files, CAPA, and complaint management in one system. MasterControl is a common enterprise alternative for larger teams. For regulatory submission and clinical data management, many early-stage teams use Veeva Vault RIM or simpler document-control tools before graduating to a full eQMS once headcount and submission complexity justify the cost. Naming the specific platform you'll run on, not just "quality management software", signals to a reviewer that you've actually budgeted and scoped this line item rather than treating it as boilerplate.

FDA, MHRA & International Regulatory Pathways

Regulatory strategy is the single highest-stakes section of a neurostimulator business plan. A reviewer who understands this space reads the regulatory section first, and vague or generic licensing language destroys credibility instantly. Below are the specific pathways, fees, and timelines for the US, UK, and two other jurisdictions.

United States, FDA Regulatory Pathways

• Premarket Approval (PMA), Class III implantable neurostimulators: Required for spinal cord stimulators, deep brain stimulators, and vagus nerve stimulators. FDA application fee $483,560 standard / $120,890 small-business rate for FY2025/26. The FDA's review clock is 180 days, but major amendment requests routinely extend real-world timelines. Total time-to-clearance including a pivotal clinical study realistically runs 3-5 years.
• 510(k) Premarket Notification, Class II non-invasive devices: Standard fee $24,062, small-business rate $6,016 for FY2026. FDA's review target is 90 days; realistic clearance including one review cycle is 4-9 months.
• Investigational Device Exemption (IDE) for pivotal trials: $50K-$250K in application/administrative cost plus full trial cost of $2M-$15M depending on indication and patient count. FDA reviews IDE applications within 30 days; enrollment and follow-up typically run 18-36 months.
• ISO 13485:2016 QMS certification: $25K-$80K initial certification through an accredited Notified Body such as BSI or TÜV SÜD, with $8K-$20K/yr surveillance audits. Budget 6-12 months to reach certification-ready state.
• Reimbursement/CPT coding strategy: Not a licence, but functionally mandatory, most payers require a device to map to an existing CPT/HCPCS code or pursue a Category III code before covering the procedure. Build this into your regulatory timeline, not as an afterthought.

United Kingdom, MHRA, UKCA & NICE

• UKCA marking (Class III implantable devices): Notified Body conformity assessment fees typically £40K-£250K depending on device class and chosen Notified Body. The UKCA transition period for CE-marked devices already on the UK market has been extended to 30 June 2028, but new devices should budget 12-24 months for full conformity assessment.
• MHRA registration (UK Responsible Person / manufacturer): £240 device registration fee per generic device group. Processed within weeks once the technical file is complete.
• Clinical Investigation Authorisation (Medical Devices Regulations 2002, SI 2002/618, as amended): £4,700 application fee (2025/26 schedule), with a 60-day statutory MHRA review period before a clinical investigation can begin.
• NICE Medical Technologies Evaluation Programme (MTEP): Not mandatory but strongly recommended before seeking NHS commissioning, typically adds 12-18 months post-UKCA but materially improves adoption odds within NHS trusts.

International, EU and Australia

• EU: Medical Device Regulation (MDR 2017/745) CE marking via a Notified Body. Implantable neurostimulators are Class III under MDR Rule 8, requiring full technical documentation review and UDI submission to EUDAMED. Certification typically costs €150K-€600K and takes 18-30 months given current Notified Body capacity constraints.
• Australia: Therapeutic Goods Administration (TGA) inclusion in the Australian Register of Therapeutic Goods (ARTG). Class III implantable devices require a Conformity Assessment Certificate, though mutual recognition is accepted from CE-marked devices under the TGA/EU Mutual Recognition Agreement where applicable.

A generic "get FDA approval" line in a business plan is an immediate credibility problem with any medtech-literate reader. An Avvale bespoke business plan maps the exact pathway, fee schedule, and realistic timeline for your specific device classification, we do not reuse one healthcare template across implantable devices, non-invasive devices, and clinics, because the economics genuinely differ.

Revenue Model & Reimbursement Reality

Implantable neurostimulator systems (device + leads + external programmer) typically list between $18,000 and $35,000 per system in the US, reimbursed via established CPT/HCPCS codes once Medicare or private-payer coverage criteria are met. Non-invasive wearable neurostimulation devices retail between $200 and $3,500, sold either direct-to-consumer or through partner clinics. Neuromodulation therapy clinics bill per-session or per-implant episode of care, typically $2,500 to $9,000 per patient.

Gross margins across the neurostimulation device category range from 55% to 78% depending on manufacturing scale and component sourcing; net margins after regulatory amortization, clinical education spend, and overhead settle at 22-41% once a company reaches meaningful volume.

Worked Example, Class II Wearable Device

A non-invasive neurostimulation device startup selling a wearable chronic-pain device at $895 direct-to-consumer, with a landed cost of goods of $210 (23.5% COGS), achieves a 76.5% gross margin per unit. At 3,200 units sold in Year 1, split between direct-to-consumer sales and roughly 40 partner clinics, that generates $2.86M in gross revenue. After a customer acquisition cost of approximately $310/unit and fixed regulatory/QMS overhead, net margin lands around 24% once annual volume clears roughly 2,500 units, the point at which fixed compliance overhead is fully absorbed by unit volume.

Reimbursement Strategy Belongs in Year One Planning, Not Year Three

The single biggest gap in weak neurostimulator business plans is treating reimbursement as a problem to solve after clearance. Payers in the US require documented clinical evidence tied to a specific CPT code before committing to coverage, and in the UK, NHS commissioning runs through NICE's Medical Technologies Evaluation Programme, which typically adds 12-18 months after UKCA marking. Build the reimbursement evidence plan into your regulatory timeline from the start, it directly determines how fast Year 1 revenue can actually materialize after clearance.

Revenue Model Comparison by Business Type

Whichever model your plan describes, the financial narrative an investor or lender wants to see is the same: a clear line from unit economics, through acquisition cost (clinical or consumer), to a stabilised net margin, with every assumption tied to a named source or a clearly labelled estimate, not a generic "healthcare industry average."

Market Size & Competitive Landscape

The global neurostimulation devices market was valued at approximately $8.16B in 2024, according to Grand View Research, and is projected to reach $16.9B by 2030 at a 12.9% compound annual growth rate. A separate estimate from Fortune Business Insights puts the 2024 baseline slightly lower at $7.32B, rising to $16.48B by 2032, the spread reflects differing scope (some reports include cochlear implants and sacral neuromodulation, others don't).

Who You're Competing Against

Medtronic (Minneapolis, MN) is the clear market leader across spinal cord stimulation and deep brain stimulation. Boston Scientific (Marlborough, MA) competes closely with its Precision SCS platform, and Abbott (Austin, TX, via the former St. Jude Medical) offers the Proclaim and Eterna systems. LivaNova (London/Houston) holds a strong position in vagus nerve stimulation for epilepsy. The most instructive comparisons for a new entrant are the venture-backed disruptors: Nevro Corp (Redwood City, CA) built a standalone public company around high-frequency SCS technology, Saluda Medical (Sydney, Australia) has differentiated on closed-loop, feedback-controlled stimulation, and Neuros Medical (Willoughby, OH) is pursuing peripheral nerve stimulation for post-amputation pain as a venture-stage company, proof that a well-capitalized, tightly-focused entrant can carve out a defensible niche against the four incumbents.

Most new entrants win not by competing head-on for SCS or DBS market share, but by targeting an indication or delivery mechanism (closed-loop feedback, a specific chronic pain subtype, a lower price point for a defined patient population) the incumbents have deprioritized because it doesn't move the needle on their scale.

Operations Plan: Manufacturing, Quality & Post-Market Surveillance

Operations for a neurostimulator device company look nothing like operations for a typical services business, and a plan that describes "staffing and scheduling" without naming the specific quality and manufacturing controls this category requires will not survive investor or lender diligence.

Core Operational Workstreams

• Design controls under 21 CFR Part 820 (US) or ISO 13485 (UK/EU): every design change, verification test, and validation study must be documented in a formal Design History File before submission, this is not optional paperwork, it is the evidentiary backbone of your FDA or MHRA submission.
• Contract manufacturing oversight: even with a qualified CDMO, the company retains legal responsibility for device quality. Budget for a dedicated quality engineer to audit supplier performance quarterly, not annually.
• Post-market surveillance and vigilance reporting: once cleared, the FDA requires Medical Device Reports (MDRs) for adverse events within specific timeframes, and MHRA requires equivalent Field Safety Corrective Action reporting. Build a complaint-handling system before your first commercial unit ships, not after the first complaint arrives.
• Inventory and lot traceability: implantable devices require full lot-level traceability from raw material to patient, typically managed through a dedicated Quality Management System software platform (see the tools section below) rather than spreadsheets once volume exceeds a few hundred units per year.

Year-One Operating Priorities

• Finalize the Design History File and risk management file (ISO 14971) well ahead of your target submission date, most delays in this category come from incomplete documentation, not device performance issues.
• Qualify a second-source supplier for every safety-critical component before scaling past initial launch volume.
• Stand up a complaint-handling and vigilance-reporting process with clear escalation timelines before first commercial shipment.
• Define the reimbursement evidence-generation plan (registries, post-market studies) as an operating workstream with its own budget and owner, not an afterthought once revenue starts.

The businesses that scale smoothly in this category are the ones that treat quality systems and regulatory operations as core infrastructure from day one, retrofitting a proper QMS onto a company that already has product in the field is dramatically more expensive than building it in from the start.

Common Mistakes Founders Make

• Treating the FDA pathway as a checkbox rather than the central driver of the financial model. A Class III PMA can consume 60-70% of total pre-revenue capital, if your budget doesn't reflect that, a diligenced investor will notice immediately.
• Underestimating clinical trial cost and duration. If your device requires an IDE-supported pivotal study, 18-36 months of enrollment and follow-up is typical, not the 6-9 months many first-time founders assume.
• Blending device-maker economics with clinic/service-provider economics in the same plan. These are structurally different businesses with different margin profiles, and investors spot the conflation instantly.
• Ignoring post-market surveillance and UKCA/MDR transition costs. Clearance is not the finish line, ongoing vigilance reporting, periodic safety updates, and eventual re-certification all carry real budget line items.
• Designing the device before designing the reimbursement strategy. A device with no clear CPT code pathway or NICE evaluation plan can clear FDA/MHRA review and still fail commercially because no payer will cover it.
• Sourcing critical components from a single contract manufacturer with no qualified second source. This single-point-of-failure risk is one of the most common gaps flagged in medtech supply-chain diligence.

Questions Buyers Are Asking

What is the difference between spinal cord stimulation and deep brain stimulation devices?

Spinal cord stimulation (SCS) implants leads in the epidural space to interrupt pain signals before they reach the brain, primarily for chronic back and limb pain. Deep brain stimulation (DBS) implants electrodes directly into targeted brain structures, commonly the subthalamic nucleus, mainly for Parkinson's disease, essential tremor, and dystonia. DBS requires stereotactic neurosurgery and carries materially higher clinical risk, regulatory scrutiny, and selling price than SCS.

How much does it cost to get FDA approval for a medical device?

It depends entirely on classification. Class II devices use the 510(k) pathway ($24,062 standard fee, $6,016 small-business rate, typically 4-9 months). Class III devices like implantable neurostimulators require full PMA ($483,560 standard fee, $120,890 small-business rate) and realistically 3-5 years including a pivotal clinical study.

Are neurostimulator devices covered by insurance?

Most FDA-approved implantable neurostimulators carry established CPT/HCPCS codes and are covered by Medicare and most private US payers once a required trial period demonstrates symptom improvement. Coverage for newer indications or non-invasive wearable devices is inconsistent and often cash-pay. In the UK, NHS coverage runs through NICE technology appraisals, adding 12-18 months after UKCA/CE marking before routine commissioning.

What companies make neurostimulation devices?

Medtronic, Boston Scientific, and Abbott dominate the implantable segment. Nevro Corp is the notable venture-backed pure-play in high-frequency SCS. LivaNova specializes in vagus nerve stimulation. Saluda Medical has pioneered closed-loop SCS, and Neuros Medical is a venture-stage peripheral nerve stimulation company, a useful comparison set for your competitive analysis section.

How long does an implantable neurostimulator battery last?

Non-rechargeable implantable pulse generators typically last 3-9 years depending on stimulation settings, requiring a surgical replacement procedure at end of life. Rechargeable systems, recharged transcutaneously on a weekly or daily basis, typically last 9-15 years. Battery life directly affects the total cost of ownership argument your business plan should model when comparing device generations.

Sample Business Plan Preview

Preview the structure and financial outputs a buyer receives. These visual mockups reflect the Model 2 (Class II wearable device) worked example used throughout this page.

What's in the Template

Every Avvale business plan template includes these sections, pre-structured for your industry:

• Executive Summary, Your business at a glance, written to hook investors in 60 seconds
• Company Overview, Legal structure, ownership, location, and founding story
• Industry Analysis, Market size, growth trends, and regulatory landscape
• Customer Analysis, Target demographics, pain points, and spending patterns
• Competitor Analysis, Competitive mapping and your differentiation strategy
• Marketing Plan, Channels, messaging, and customer/clinical acquisition strategy
• Operations Plan, Day-to-day workflows, staffing structure, and key milestones
• Management Team, Founder bios, advisory board, and key hires planned

The optional Financial Forecast add-on (included in our $300/£250 and $1,000/£800 packages) provides a 5-year Excel model with income statement, cash flow, balance sheet, break-even analysis, and startup capital requirements, including a regulatory-milestone-linked cash burn schedule, which is the section generalist financial templates almost always miss for medtech businesses.

Frequently Asked Questions

Related Reading

• Building a device-adjacent business instead? See our Medical Device Development Business Plan Template for the broader regulatory and QMS framework that applies across device categories.
• Not sure which package fits your stage? Compare options on the Business Plan Writer page.
• Read real client outcomes across healthcare and other sectors in our Case Studies library.
• Start with the no-cost option: Free Business Plan Template hub.